New York, NYCIK 18587035 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
80 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Engene Holdings Inc | 3.36M | $30.35M | 9.4% | +82.8K | Added |
| 2 | Nuveen Churchill Direct Lend | 2.14M | $28.60M | 8.8% | −947.9K | Reduced |
| 3 | Blue Owl Capital Corporation | 2.05M | $26.12M | 8.1% | 0 | Held |
| 4 | Larimar Therapeutics Inc |
| 6.82M |
| $26.00M |
| 8.0% |
| +970.6K |
| Added |
| 5 | Cullinan Therapeutics Inc | 2.35M | $24.33M | 7.5% | −160.0K | Reduced |
| 6 | Compass Therapeutics Inc | 3.47M | $18.62M | 5.7% | +875.0K | Added |
| 7 | Holley Inc | 4.15M | $17.13M | 5.3% | −715.7K | Reduced |
| 8 | Context Therapeutics Inc | 7.43M | $10.93M | 3.4% | +25.0K | Added |
| 9 | Conduent Inc | 4.82M | $9.26M | 2.9% | +365.6K | Added |
| 10 | Repare Therapeutics Inc | 3.44M | $8.95M | 2.8% | 0 | Held |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio